Biophys J, 2025, 124(7):1073-1084

The role of peptide conformation presented by MHC in the induction of TCR triggering

High resolution crystal structure of stimulatory peptide-MHC (pMHC) ligands bound to TCR revealed different conformation of the two peptides at positions P6 and V7 compared to the conformation of the same peptides presented by unliganded MHC. Supercomputer simulation and well-tempered metadynamics approach revealed several meta-stable non-canonical TCR-pMHC interactions that depend on the conformation of the MHC-bound peptides. The diversity of meta-stable states was significantly more represented in signaling TCR-pMHC complex. These findings suggest that TCR-pMHC recognition can be informed by a conformation of peptide presented by MHC that notably influences the orientation of TCR recognizing pMHC ligand. It appears that TCR bound to stimulatory pMHC possess a significantly higher degree of freedom to assume various metastable TCR orientations which are distinct from canonical docking. In contrast, TCR interacting with non-stimulatory pMHC ligand revealed markedly less meta-stable non-canonical interactions and disengaged from the pMHC. This suggests that productive TCR-mediated signaling may depend on non-canonical interactions between TCR and pMHC, either facilitating early recognition events or providing new contacts for catch-bond formation. Our discovery can inform future attempts to simulate the catch-bond formation mechanism in TCR-pMHC recognition, allowing the formation of new bonds mediating alternative peptide presentation.

Golovin AV, Panteleev S, Zlobin AS, Anikeeva N, Smirnov I, Gabibov A, Sykulev Y

IBCH: 11813
Ссылка на статью в журнале: https://linkinghub.elsevier.com/retrieve/pii/S0006349525000591
Нет данных о цитировании
Данные статьи проверены модераторами 2025-03-17

Список научных проектов, где отмечена публикация

  1. CA217714. . Внебюджетное финансирование.
  2. Определение оптимальных взаимодействий ТКР-пГКГС: использование для разработки новых терапевтических средств на основе Т-клеток для лечения вирусных инфекций и рака (6 Января 2017 года — 31 Декабря 2019 года). Смирнов И.В.. Грант, РФФИ.
  3. Разработка каталитического антитела к RBD домену S-белка вируса SARS-CoV-2 (6 Января 2021 года — 31 Декабря 2024 года). Головин А.В.. Грант, РНФ.